Samsung Biologics Co.,Ltd. (KRX:207940)

Samsung Biologics Revenue

Samsung Biologics had revenue of 1.66T KRW in the quarter ending September 30, 2025, with 39.86% growth. This brings the company's revenue in the last twelve months to 5.50T, up 26.13% year-over-year. In the year 2024, Samsung Biologics had annual revenue of 4.55T with 23.08% growth.

• Revenue (ttm): 5.50T
• Revenue Growth: +26.13%
• P/S Ratio: 14.23
• Revenue / Employee: 1.15B
• Employees: 4,770
• Market Cap: 78.32T

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2024	4.55T	852.73B	23.08%
Dec 31, 2023	3.69T	693.29B	23.10%
Dec 31, 2022	3.00T	1.43T	91.41%
Dec 31, 2021	1.57T	403.23B	34.62%
Dec 31, 2020	1.16T	463.19B	66.02%